TMBIM4 and hepatocellular carcinoma: Similar to our previous study,21 another two S1R antagonists (BD1063 and BD1047)26 increased sorafenib‐induced HCC cell death, while the S1R agonist PRE‐084 had no effect on cell death (Figure 3D).